Population pharmacokinetics of carbamazepine in Chinese epilepsy patients

Therapeutic Drug Monitoring

Volumn 25, Issue 3, 2003, Pages 279-286

  Jiao, Zheng ^a   Zhong, Ming kang ^a   Shi, Xiao jin ^a   Hu, Min ^a   Zhang, Jing hua ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Carbamazepine; Chinese epilepsy patients; NONMEM; Population pharmacokinetics

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ARTICLE; BODY WEIGHT; CHINESE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARBAMAZEPINE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHINA; CONFIDENCE INTERVALS; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 0038780591     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200306000-00005     Document Type: Article

References (29)

1. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10, 11-epoxide. An update. Clin Pharmacokinet. 1986;11:177-198.
2. Liu H, Delgado MR. Influence of sex, age, weight and carbamazepine dose on serum concentrations, concentration ratios and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit. 1994;16:469-476.
3. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem. 1998;44:1085-1095.
4. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet. 1996;31:198-214.
5. Zheng P, Hu MY, Liu ST, et al. Preliminary Analysis on Multiplepeak phenomenon of carbamazepine. China Pharmacy. 1999;10:45.
6. Zhang RN, Qu ZP, Yu LY, et al. Comparison on bioavailability of domestic and imported carbamazepine tablets in normal volunteers. Chinese J Pharm. 1990,21:544-545.
7. Yukawa E and Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol. 1996;36:752-759.
8. Delgado Iribarnegaray MF, Santo Bueldga D, Garcia Sanchez MJ, et al. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit. 1997;19:132-139.
9. Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol. 1998, 54:359-362.
10. Graves NM, Brundage RC, Wen Y, et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy. 1998;18:273-281.
11. Chan E, Lee SH, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol. 2001;51:567-576.
12. Reith DM, Hooper WD, Parke J, et al. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents and adults. J Pharmacokinet Biopharm. 2001;28:79-92.
13. Wade JR, Kelman AW, Howie CA, et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm. 1993;2:209-222.
14. Kowalski KG and Hutmacher MM. Design evaluation for a population pharmacokinetics study using clinical trial simulations. Stat Med. 2001;20:75-91.
15. Vladimir P, Holford N, Wright JG, et al. Covariate models using weight. Available at: http://www.cognigencorp.com/nonmem/nm/97nov171999.html. Accessed October 21, 2002.
16. Boeckman AJ, Sheiner LB, Beal SL. NONMEM Users Guide Part V. San Francisco: University of California at San Francisco; 1994.
17. Mandema JW, Verotta D, Sheiner LB. Building population pharmcokinetic-pharmcodynamic models. I models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-528.
18. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
19. FDA. Guidance for Industry - population pharmacokinetics, Feb 1999. Available at: http://www.fda.gov/cder/guidance/index.htm.
20. Thomas E. Lackner Strategies for Optimizing Antiepileptic Drug Therapy in Elderly People. Pharmacotherapy. 22:329-364, 2002.
21. Hockings N, Pall A, Moody J, et al. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol. 1986;32:232-236.
22. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia. 43;2002:365-385.
23. Baciewicz AM. Carbamazepine drug interaction. Ther Drug Monit. 1986;8:305-317.
24. Svinarov DA, Pippenger CE. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase? Ther Drug Monit. 1995;17:217-220.
25. Levy RH, Moreland TA, Morselli PL, et al. Carbamazepine valproic acid interaction in man and rhesus monkey. Epilepsia. 1984,25:338-345.
26. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1987;9:298-303.
27. Liu H, Delgado M. Serum and intrinsic clearance of carbamazepine in pediatric epilepsy patients and the influence of comedication. Epilepsia. 1993;34 (suppl 6):S115.
28. Deleu D, Aarons L, Ahmed IA. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol. 2001;57:243-248.
29. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet. 1986;11:387-401.